6:30 PM – 7:00 PM Dinner and Registration
7:00 PM – 7:10 PM Welcome and Introduction
7:10 PM – 7:20 PM Overview of HCC Therapy
7:20 PM – 7:45 PM Selection of First-line Therapy in Advanced, Unresectable HCC
7:45 PM – 8:10 PM Incorporating Immune Checkpoint Inhibitors Into Treatment For Patients With HCC
8:10 PM – 8:35 PM Targeted Therapy Options in the Second-line Setting for Advanced HCC
8:35 PM – 9:00 PM Final Thoughts, Take-home Conclusions, and Q&A Session
Date / Time
San Francisco, California
Park Central Hotel San Francisco
Andrew X. Zhu, MD
Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Stacey Stein, MD
Assistant Professor of Medicine
Department of Medical Oncology
Yale Cancer Center
New Haven, Connecticut
The goal of this program is to improve learners’ knowledge and competence in applying the latest treatment approaches and interdisciplinary collaborative strategies towards optimal care of patients with hepatocellular carcinoma.
This program is intended for interventional radiologists, oncologists, hepatologists, and other clinicians involved in the management of patients with hepatocellular carcinoma.
- Explore the current status of predictive biomarkers for identification and selection of patients for novel therapies and emerging molecular/immunologic classifications that could inform future biomarker-enriched clinical trial design, enabling precision oncology care in HCC
- Select optimal, individualized locoregional treatment for patients with HCC based on recent advances and evolving best practices to maximize clinical outcomes
- Review recent therapeutic advances and FDA approvals of novel systemic treatments (including targeted and immunotherapeutic agents) for patients with newly diagnosed and relapsed/refractory advanced HCC and integrate this information into clinical practice
- Plan therapeutic strategies that optimize the selection/sequence of therapies to provide the best outcome to patients with HCC in the first-line setting and for patients with advanced HCC and treatment for patients with HCC that has progressed on or after 1 or multiple lines of therapy, taking into consideration the available clinical evidence, known agent toxicity/ tolerability profiles, expert recommendations, and patient preferences
- Assess the safety profiles of targeted therapies and checkpoint inhibitors used in the management of HCC
- Counsel patients to help them understand their treatment options and to be proactive, knowledgeable learners in their care
- Become familiar with the design of ongoing clinical trials for novel HCC treatment strategies, and counsel appropriate patients about availability and participation
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.